lercanidipine bijon 20 mg filmdragerad tablett
uab bijon medica - lerkanidipinhydroklorid, vattenfri - filmdragerad tablett - 20 mg - lerkanidipinhydroklorid, vattenfri 20 mg aktiv substans; laktosmonohydrat hjälpämne
naproxen apofri 250 mg tablett
evolan pharma ab - naproxen - tablett - 250 mg - laktosmonohydrat hjälpämne; naproxen 250 mg aktiv substans
eletriptan 2care4 40 mg filmdragerad tablett
2care4 aps - eletriptanhydrobromid - filmdragerad tablett - 40 mg - para-orange aluminiumlack hjälpämne; sojalecitin hjälpämne; laktos (vattenfri) hjälpämne; eletriptanhydrobromid 48,462 mg aktiv substans
exolyt oral lösning
nevada pharma ab - ammoniumklorid; guaifenesin; klorcyklizinhydroklorid - oral lösning - etanol, vattenfri hjälpämne; klorcyklizinhydroklorid 2 mg aktiv substans; ammoniumklorid 5 mg aktiv substans; sorbitol hjälpämne; guaifenesin 20 mg aktiv substans
siltra xpro
bayer ag - acetylsalicylsyra - tablett - 500 mg - acetylsalicylsyra 500 mg aktiv substans - acetylsalicylsyra
kalydeco
vertex pharmaceuticals (ireland) limited - ivacaftor - cystisk fibros - andra andningsorganprodukter - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 och 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 och 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.
altermol 500 mg/30 mg tablett
alternova a/s - kodeinfosfathemihydrat; paracetamol - tablett - 500 mg/30 mg - paracetamol 500 mg aktiv substans; kodeinfosfathemihydrat 30 mg aktiv substans; laktosmonohydrat hjälpämne
symkevi
vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cystisk fibros - andra andningsorganprodukter - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.
coldmexin 8 mg tablett
orifarm generics a/s - bromhexinhydroklorid - tablett - 8 mg - bromhexinhydroklorid 8 mg aktiv substans; laktosmonohydrat hjälpämne